Scienture Reports 216% Revenue Surge, Gross Margin Hits 76.8% with Arbli™ and REZENOPY™ Patents
Net revenue rose 216% year-over-year to $431,609 in 2025, while gross margin expanded 7240 basis points to 76.8%, driven by initial sales of liquid losartan Arbli™. The company ended the year with $6.7 million in cash, $5.2 million in working capital, and secured extensive GPO and patent coverage for Arbli™ and REZENOPY™.
1. 2025 Financial Results
Net revenue increased 216% to $431,609, gross margin expanded 7,240 basis points to 76.8%, and gross profit rose to $331,482 from $6,005. Operating expenses totaled $42.9 million, including a $26.3 million non-cash impairment, resulting in a net loss of $41.5 million; the company ended the year with $6.7 million in cash and $5.2 million in positive working capital.
2. Commercial and Operational Highlights
The company secured multiple PBM-led and institutional GPO rebate agreements and achieved formulary inclusion with major national health plans, extending Arbli™ coverage to over 100 million lives. It received Orange Book-listable patents for both Arbli™ and REZENOPY™, and established a collaboration with BlinkRx to enhance patient access, fulfillment, and adherence.
3. 2026 Outlook
Management expects continued momentum for Arbli™ in the U.S. losartan market and plans the commercial launch of REZENOPY™ in Q2 2026 as the highest-dose FDA-approved naloxone nasal spray. Scienture is also evaluating additional acquisition opportunities to expand its specialty pharmaceutical portfolio and drive long-term growth.